France· FR:69786114
TRESIBA PENFILL 100 unités/ml, solution injectable en cartouche
A medicinal product containing insuline dégludec, registered in France by NOVO NORDISK (DANEMARK), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- INSULINE DÉGLUDEC
- Manufacturer
- NOVO NORDISK (DANEMARK)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009268533895 cartouche(s) en verre de 3 mlEUR 46.85
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insuline dégludec in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTRESIBANovo Nordisk A/S, Bagsvaerd
- United StatesInsulin DegludecNovo Nordisk Pharma, Inc.
- BelgiumRyzodeg 100 U/mlNovo Nordisk
- United KingdomTresiba FlexTouch 100units/ml solution for injection 3ml pre-filled pensNovo Nordisk Ltd
- FinlandTresibaOrifarm Oy
- SpainTRESIBA 100 UNIDADES/ML FLEXTOUCH SOLUCION INYECTABLE EN PLUMA PRECARGADANovo Nordisk A/S
- SwedenTresiba FlexPen 100 enheter/ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- SwitzerlandTresiba FlexTouch 100 E/ml, InjektionslösungNovo Nordisk Pharma AG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tresiba Flexpen, Tresiba Flextouch
- Norway · Tresiba, Tresiba Flexpen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c22b9316-c927-45b1-8e1c-a77e2afe131f GET /v1/drugs/c22b9316-c927-45b1-8e1c-a77e2afe131f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69786114",
"date_amm": "2013-01-21",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/12/807",
"substance": "INSULINE DÉGLUDEC",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about insuline dégludec.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.